Sheikh K M, Apuzzo M L, Kochsiek K R, Weiss M H
Yale J Biol Med. 1977 Jul-Aug;50(4):397-403.
There is increasing evidence that human tumors possess tumor-associated neo-antigens. The host mounts an immunological response to these antigens, as evidenced by the detection of circulating humoral antibodies in a variety of human neoplasia.An indirect immunofluorescent antibody technique was employed to detect antibodies to tumor-associated antigens in the sera of patients with malignant gliomas. Viable single cell suspensions were used to demonstrate antibodies to surface contents of tumor cells and cell preparations were snap-frozen at -160° C to demonstrate antibodies to cytoplasmic components of tumor cells. After incubation with serum, the preparations were treated with polyvalent sheep antihuman globulin conjugated to isomer-1-fluorescein isothiocyanate, washed, and examined with a Leitz incident fluorescent microscope.Of the 17 sera from histologically proven malignant glial neoplasm patients, 2 (11%) were positive for an autologous surface antibody reaction. Five (23%) of 21 were positive for an autologus cytoplasmic antibody, however, 10 (47%) of 21 of the sera gave a positive reaction for cross-reacting cytoplasmic antibodies when tested with a battery of tumor cells obtained from different patients with malignant glial tumors.No reaction was observed with normal brain tissue. Absorption studies indicated the presence of a tumor-associated antigen.This study demonstrated that certain patients with malignant gliomas possess circulating antibodies to cytoplasmic components of their own tumor cells. The fact that a number of sera cross-reacted with tumor cells obtained from different patients suggests that antigenic cross-reactivity exists between malignant glioma cells from different patients. It is suggested that with further refinement, immunofluorescent detection of antibodies could evolve as a useful diagnostic adjunct in malignant glioma.
越来越多的证据表明,人类肿瘤具有肿瘤相关新抗原。宿主会对这些抗原产生免疫反应,这在多种人类肿瘤中检测到循环体液抗体得到了证实。采用间接免疫荧光抗体技术检测恶性胶质瘤患者血清中针对肿瘤相关抗原的抗体。使用活的单细胞悬液来检测针对肿瘤细胞表面成分的抗体,并将细胞制剂在-160℃速冻以检测针对肿瘤细胞胞质成分的抗体。与血清孵育后,制剂用与异硫氰酸荧光素异构体-1偶联的多价羊抗人球蛋白处理,洗涤后,用徕卡落射荧光显微镜检查。在17例经组织学证实为恶性胶质肿瘤患者的血清中,2例(11%)自身表面抗体反应呈阳性。21例中有5例(23%)自身胞质抗体呈阳性,然而,当用从不同恶性胶质肿瘤患者获得的一组肿瘤细胞进行检测时,21例血清中有10例(47%)交叉反应胞质抗体呈阳性反应。与正常脑组织未观察到反应。吸收研究表明存在肿瘤相关抗原。本研究表明,某些恶性胶质瘤患者血清中存在针对自身肿瘤细胞胞质成分的循环抗体。许多血清与从不同患者获得的肿瘤细胞发生交叉反应,这一事实表明不同患者的恶性胶质瘤细胞之间存在抗原交叉反应。有人认为,随着进一步完善,抗体的免疫荧光检测可能会发展成为恶性胶质瘤一种有用的诊断辅助手段。